Date: 2011-05-24
Type of information: Distribution agreement
Compound: denosumab
Company: AstraZeneca (UK) Daiichi Sankyo (Japan)
Therapeutic area: Cancer - Oncology
Type agreement: Co-promotion
Action mechanism:
Disease: bone disorders stemming from bone metastasis
Details: AstraZeneca has announced a co-promotion agreement in Japan with Daiichi Sankyo for denosumab for the treatment of bone disorders stemming from bone metastasis. AstraZeneca and Daiichi Sankyo will co-promote denosumab after it is approved for use in Japan. In Japan, Daiichi Sankyo acquired denosumab rights in 2007 from Amgen Inc. The company filed a Japanese New Drug Application (JNDA) in August 2010.
Financial terms: Financial terms of this agreement are not disclosed.
Latest news:
